Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
about
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection.Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection.Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.Total chemical synthesis of human interferon alpha-2b via native chemical ligationBlocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activationCD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosisTat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccineHIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alphaToward a new generation of vaccines: the anti-cytokine therapeutic vaccines.HIV-1 immunopathogenesis: how good interferon turns bad.Plasmacytoid dendritic cells in HIV infection.IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine modelImmune activation and collateral damage in AIDS pathogenesis.Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines.Immunotherapy in asthma.Cognitive consequences of a sustained monocyte type 1 IFN response in HIV-1 infectionType I interferon: understanding its role in HIV pathogenesis and therapy.Targeting the gastrointestinal tract to develop novel therapies for HIV.Gene therapy with plasmids encoding IFN-β or IFN-α14 confers long-term resistance to HIV-1 in humanized mice.Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines.The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model[Auto-vaccines: an immunological alternative to gene silencing].[Anti-viral treatment: pro or cons type I IFN?].Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice.
P2860
Q26865388-3E226236-E5C4-40AD-8A45-6A3893F54E97Q33828349-EF0BFB8F-73BE-4BDB-B604-1A03CD6ACAC4Q34346743-AAF4C632-343B-4817-9F7F-718600193B7BQ34413235-B58ABFEB-3ABF-480A-8E91-4463B511449EQ34557110-34EF8904-94E9-4C5D-A27D-5A997A92587DQ35001008-46D69624-1B75-44B5-9752-2CAE8A6DB2D0Q35114827-374A42EB-E5C7-4504-B277-4EF51C051499Q35587022-C0DA3559-5F8A-4BC8-866C-D4B700D6061EQ35606616-0BD296C7-57A9-47BA-B0A7-F49C069E8927Q35847699-759CF4ED-9AA1-4A83-9CBC-63D2CCDC2798Q35993736-A3C1E6E1-0242-4BA5-9909-439D999C6287Q36141492-3DB64806-DCC9-4A0F-A041-FF10E4B7210FQ36536313-C1F7988C-BC39-46B6-8AF8-EB4C056F5D8EQ36656715-61164DBD-C51D-472A-8B6C-15052809A94CQ37019332-C237F64F-C008-438A-BF0A-E050FEEE43C2Q37125180-3D0FFC25-87AB-4DAB-9072-1A2C629974AEQ37199493-49824CB7-A3AE-44AB-82DB-A928AD8D4A53Q37773243-61185154-20E1-4326-85F9-30BA4C5128E3Q37773295-24588B40-B055-4D4D-89E4-83BFDF81F6A6Q37793242-DE61AC11-21D9-4186-AA37-CEED1C0C49DEQ38214994-EBF9397C-2F16-4F82-AE22-91DA12044110Q38348388-D1E9F5E3-AB27-4A8E-9841-2D977EEC57FDQ38548095-045B181F-0ABB-445C-8C33-A3270C4C397AQ40510052-A0D4CB86-CE1D-4E1E-A4F4-D8960E8D625BQ41381866-0C97116E-83FE-4C8D-B80C-C16BDCC9AC92Q42235552-0C8F2B90-FE88-46B9-9E64-2494A6528CCFQ43691412-03509E8C-5088-4C0E-A9BE-E0E8B68ED67DQ43834390-2E0AC751-8A5D-4EBE-9CF7-04D62643317FQ51001680-98E980E4-DB10-498D-80F4-B0264B799904
P2860
Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Active anti-interferon-alpha i ...... ed patients (the EURIS study).
@en
type
label
Active anti-interferon-alpha i ...... ed patients (the EURIS study).
@en
prefLabel
Active anti-interferon-alpha i ...... ed patients (the EURIS study).
@en
P2093
P921
P1476
Active anti-interferon-alpha i ...... ed patients (the EURIS study).
@en
P2093
A Bergamasco
A Gringeri
E Santagostino
Z Bentwich
P304
P356
10.1097/00042560-199904010-00006
P407
P577
1999-04-01T00:00:00Z